Avandaryl Approval On Track Despite Consent Decree, GSK Says
Executive Summary
GlaxoSmithKline is confident FDA will approve its diabetes line extension agent Avandaryl on schedule despite the fact that the manufacturing facility for the product is operating under a GMP consent decree
You may also be interested in...
GSK’s Avandaryl Approved, But Manufacturing Changes Are Still Pending
GlaxoSmithKline's diabetes line extension product Avandaryl has cleared FDA, but the firm plans to move manufacturing for commercial supply of the drug out of its problematic Puerto Rico plant
GSK’s Avandaryl Approved, But Manufacturing Changes Are Still Pending
GlaxoSmithKline's diabetes line extension product Avandaryl has cleared FDA, but the firm plans to move manufacturing for commercial supply of the drug out of its problematic Puerto Rico plant
GSK’s Six Launches, Six Filings Slated For ’06: Sign Of R&D Strategy Payoff?
GlaxoSmithKline plans to end 2006 with six product launches and six regulatory filings, CEO J.P. Garnier said during a presentation at the Bear Stearns Healthcare conference in New York Sept. 13